# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Josephine Baker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML049-SYN-TD
- Date: 1969-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Colette Ashby-Nwosu, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- She wants to return to the stage and to have the strength to care for her children **S**
- She is afraid of another heart attack and of what would happen to her family **S**
- Debts and lost income make every cost a worry **S**

## Your goals

- Twelve months of dual antiplatelet therapy from the heart attack without interruption. Target: 1970-03-24. Recorded outcome: Seven months completed without a missed dose; changed from ticagrelor to clopidogrel without a gap. **S**
- LDL cholesterol below 70 mg/dL with at least a 50% fall. Target: 1969-07-21. Recorded outcome: LDL 62 mg/dL, a 58% fall from 146. **S**
- Blood pressure below 130/80 mmHg. Target: 1969-05-26. Recorded outcome: 126/78 in the clinic; home average 124/76. **S**
- Complete cardiac rehabilitation and return to performing. Target: 1969-07-21. Recorded outcome: Exercise test to about 10 METs without ischemia; graded return to rehearsals agreed. **S**
- Mood: PHQ-9 below 5 by twelve weeks. Target: 1969-07-21. Recorded outcome: PHQ-9 7 to 3. **S**

## What we agreed to do

- Respectful, trauma-informed shared decisions: take her account of her symptoms seriously, explain each medicine and its reason plainly, write the plan down, and check costs with her before prescribing. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association (2016); Sex and Race/Ethnicity-Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults (2016) **S**
- Cardiology consultation on the day of the two-week visit, with an echocardiogram, to find the cause of the breathlessness, review the antiplatelet choice and the other medicines, and advise on rehabilitation and a return to the stage. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026) **S**
- Dual antiplatelet therapy, aspirin 81 mg with a P2Y12 inhibitor, for twelve months from the heart attack, never stopped without speaking to cardiology; then aspirin alone. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026) **S**
- Atorvastatin 80 mg daily; lipid panel four to eight weeks after the start; goal LDL below 70 mg/dL with at least a 50% fall; lipoprotein(a) measured once. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026) **S**
- Metoprolol succinate for at least the first year after the heart attack; lisinopril for high blood pressure, with home readings and a target below 130/80 mmHg; potassium and creatinine one to two weeks after any dose change. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026) **S**
- Enroll in a 36-session outpatient cardiac rehabilitation program, starting within two weeks, with exercise training, nutrition, stress management and psychological support; the clinic will call her if she misses sessions. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association (2016); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026) **S**
- Depression after a heart attack: PHQ-2 and PHQ-9 today, repeat PHQ-9 at about twelve weeks, the rehabilitation program's psychologist, and a lower threshold for treatment if symptoms rise. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); Depression and Coronary Heart Disease: Recommendations for Screening, Referral, and Treatment: A Science Advisory From the American Heart Association (2008); Depression as a Risk Factor for Poor Prognosis Among Patients With Acute Coronary Syndrome: A Scientific Statement From the American Heart Association (2014) **S**
- Chest-pain action plan: nitroglycerin under the tongue, and 911 if pain is not better five minutes after the first tablet; warning symptoms in women, such as breathlessness, unusual tiredness, nausea or jaw, back or arm discomfort, explained. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association (2016) **S**
- Costs: generic medicines in 90-day fills, the clinic social worker for debt advice and help with medicine costs, and rehabilitation sessions at times that fit her family. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023) **S**
- Women's cardiovascular risk: record the hysterectomy of her thirties and a possible early menopause as a risk-enhancing factor; hormone therapy is not used to prevent heart disease. Guideline: Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association (2016); Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association (2020) **S**
- Change ticagrelor to clopidogrel for ticagrelor-related breathlessness: 600 mg loading dose 24 hours after the last ticagrelor, then 75 mg daily, without a gap in antiplatelet cover. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025) **S**
- Raise lisinopril to 10 mg daily for blood pressure above target, with potassium and creatinine one to two weeks later. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026) **S**
- Laboratory tests drawn at the rehabilitation center on session days, so that no check needs a separate trip. Guideline: CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026) **S**
- Nosebleed plan on dual antiplatelet therapy: firm pressure on the soft part of the nose for 15 minutes, saline spray and a humidifier; do not stop aspirin or clopidogrel; come in if bleeding lasts more than 30 minutes. Guideline: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); Clinical Practice Guideline: Nosebleed (Epistaxis) (2020) **S**
- Graded return to the stage: rehearsals at the effort reached in rehabilitation, then full performances, with rest between shows, water, and nitroglycerin in the dressing room. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023) **S**

## Follow-up

- 1969-04-14: Establishing care three weeks after a heart attack and stent, with breathlessness on exertion and tiredness: examination, ECG, laboratory tests, medicines, mood screening, cardiac rehabilitation and the chest-pain action plan **S**
- 1969-04-28: Two-week review: echocardiogram, cardiology consultation the same day, the cause of the breathlessness and the antiplatelet plan **S**
- 1969-05-26: Four-week review after the change to clopidogrel: breathlessness, blood pressure, potassium and kidney function, and cardiac rehabilitation **S**
- 1969-07-21: Twelve-week review: exercise test, lipids, mood, and the return to performing **S**
- 1969-09-15: Periodic adult preventive visit **S**
- 1969-10-20: Seven-month review: antiplatelet plan to twelve months, blood pressure, kidney function, angina status and plans for the year **S**

This teaching document does not replace care from a qualified clinician.
